ABSTRACT: Over the past 2 decades, breast-conservation therapy with lumpectomy and whole-breast radiotherapy has become a standard option for the majority of women with newly diagnosed breast cancer. Long-term local control is achieved in approximately 85% of patients, and the therapy is generally well tolerated. There can, however, be long-term effects on the breast and other nearby tissues that may range from asymptomatic findings on examination to severe, debilitating problems. Infection, fat necrosis, and severe musculoskeletal problems such as osteoradionecrosis or soft-tissue necrosis are uncommon, affecting less than 5% of patients. However, changes in range of motion, mild-to-moderate musculoskeletal pain, and arm and breast edema are much more common. As more women choose breast-conservation therapy for management of their breast cancer, physicians will encounter these problems, as well as in-breast tumor recurrence, with greater frequency. This review will focus on the incidence, contributing factors, and management of the late problems of infection, fat necrosis, musculoskeletal complications, and local recurrence following breast-conservation therapy.
Breast-conserving therapy with lumpectomy, axillary dissection, and radiotherapy, has been associated with a variety of side effects and complications. It is important to have a good understanding of the frequency and severity of treatment- related problems in order to adequately counsel patients about their treatment options. In addition, continual assessment of techniques and other factors that may influence the incidence of complications is necessary to develop safer treatment approaches. In general, the best way to manage a treatment-related problem is to avoid its occurrence. This is especially important in patients who undergo irradiation, because the options for treatment of late effects may be limited.
This review will focus on some of the less commonly discussed side effects and complications of breast-conserving surgery and radiotherapy for early-stage breast cancer such as infection, fat necrosis, musculoskeletal effects, and pain. In addition, the options for management of in-breast tumor recurrence will be reviewed.
The incidence of cellulitis or breast abscess after breast-conserving therapy is low, ranging from 1% to 5% in most case series, with an annual risk for the development of delayed cellulitis of 0.8%.[1-3] Patients may present with cellulitis or abscess in the perioperative period, or at any time before, during, or after radiation therapy.[2,4] The majority of cases present with pain, erythema, axillary swelling, and warmth in the involved breast, whereas a breast abscess or seroma may present as suspicious mammographic changes or a clinically palpable breast mass. The median latency period for the development of delayed cellulitis is 3 to 5 months postradiotherapy, and it may even occur many years after the completion of therapy.[1-3,6,7]
Although the clinical scenario in which delayed breast cellulitis commonly occurs points to a multifactorial etiology, specific risk factors have been evaluated. Brewer et al performed a matched case-control study to statistically associate potential risk factors with the development of breast cellulitis in a cohort of patients treated with breast-conserving therapy. Their analysis of 17 cases revealed that arm lymphedema was the most prominent risk factor for the development of delayed breast cellulitis. Other trials have also identified the potential role of clinical or subclinical lymphedema of the breast secondary to alteration of vascular and lymphatic flow from surgery and radiotherapy as a potential predisposing factor for the development of breast infection.
It is believed that lymphedema results in stasis within the lymphatic channels, serving as a medium for bacterial growth. Similarly, microvasculature injury or skin desquamation may play an etiologic role.[2,4,7] It is felt that in this anatomically altered setting, microtrauma to the breast may precipitate cellulitis. In addition, many reports have implicated posttreatment breast seroma and aspiration of seroma fluid with the development of cellulitis.[1,4]
Mertz et al found that radiographically demonstrable fluid collections at the lumpectomy site were present in 75% of a small cohort of patients treated for cellulitis after breast-conserving therapy. This finding may point to the presence of these fluid collections as a predisposing factor for the development of later infections.
As with a variety of other cellulitis syndromes, bacterial pathogens are often not recovered, and procedures such as aspiration of the leading edge of a lesion and blood cultures, in the absence of other systemic symptoms of infection, usually produce a low yield.[4,6] Hence, treatment is generally empiric, and choice of antibiotic treatment is influenced primarily by clinical presentation. The most frequently cultured organisms are Staphylococcus aureus or beta-hemolytic streptococci species.[4,6]
Initial treatment for mild cases consists of empiric therapy with oral antibiotics to cover normal skin flora. Penicillinase-resistant penicillins, including nafcillin and oxacillin, and first-generation cephalosporins, including cefazolin and cephalexin, are commonly selected. If S aureus is suspected, a beta-lactamase-inhibiting penicillin such as amoxicillin/ clavulanate (Augmentin) or ampicillin/ sulbactam (Unasyn) may be used. For persistent cases or for patients with leukocytosis and fever, hospital admission for a course of intravenous antibiotics may be warranted.
Although many patients will experience a relatively quick response to empiric therapy, clearance of breast changes may be gradual and may persist for extended periods (Figure 1). Cultures of abscesses or seroma aspirates may be obtained prior to the initiation of therapy to facilitate later revision of therapy as needed for patients without a clinical response. The recommended period of treatment is usually 10 to 14 days.
Incision and drainage should be considered for persistent abscess after completion of therapy. For nontoxic patients who do not respond to antibiotic therapy, a 7- to 14-day trial of nonsteroidal anti-inflammatory agents or topical corticosteroids may be warranted to treat potential dermatitis. Skin biopsy to rule out cancer recurrence should be considered in all patients who fail to respond to conservative therapy.
In addition to antibiotics, other preventive techniques to decrease lymphedema may be employed, such as compression therapy, skin care, and exercise. Patients with axillary or breast seromas should be counseled on the signs, symptoms, and treatment of cellulitis because they may be at higher risk of developing the problem.
Fat necrosis commonly presents as an indurated mass in the region of the lumpectomy scar, with overlying skin fixation, retraction, erythema, and tenderness. Some reports indicate an incidence of less than 1% on long-term follow-up of patients treated with standard breast radiotherapy.[9,10] Boyages and colleagues found a 4.5% 5-year actuarial risk of fat necrosis or fibrosis requiring surgery. The rate of fat necrosis may be significantly higher in patients treated with certain regimens of high-dose rate brachytherapy alone rather than standard whole-breast external-beam irradiation. Wazer et al found that 27% of 30 patients, who received irradiation twice daily at 340 cGy for 5 days to the lumpectomy cavity plus a 2-cm margin, developed symptomatic fat necrosis. In another report, 10% of patients treated with high-dose rate brachytherapy (372 cGy twice daily for 5 days) developed fat necrosis within 4 to 18 months. The average time to onset of symptoms is approximately 12 months posttherapy. In most patients, the presentation of fat necrosis clinically mimics that of recurrent tumor. Mammographic evaluation is helpful in identifying the lesion if characteristic changes such as radiolucent oil cysts are present. However, fat necrosis may also appear on mammography as round opacities, dystrophic calcifications, and clustered pleomorphic calcifications. Given the often confusing clinical presentation and inconclusive imaging, ultrasound-guided core biopsy should be performed in all patients, even those with a history of breast trauma predating the appearance of their lesion. If local symptoms of discomfort persist, excision may be considered in selected patients.
1. Brewer VH, Hahn KK, Rohrbach BW, et
al: Risk factor analysis for breast cellulitis
complicating breast conservation therapy. Clin
Infect Dis 31:654-659, 2000.
2. Miller SR, Mondry T, Reed JS, et al:
Delayed cellulitis associated with breast conservative
therapy for breast cancer. J Surg
Oncol 67:242-245, 1998.
3. Staren E, Klepac S, Smith A, et al: The
dilemma of delayed cellulitis after breast conservation
therapy. Arch Surg 131:651-654,
4. Hughes LL, Styblo TM, Thoms WW, et
al: Cellulitis of the breast as a complication of
breast-conserving surgery and irradiation. Am
J Clin Oncol 20:338-341, 1997.
5. Keidan R, Hoffman J, Weese J, et al:
Delayed breast abscesses after lumpectomy
and radiation therapy. Am Surg 56:440-444,
6. Baddour LM: Breast cellulitis complicating
breast conservation therapy. J Intern Med
7. Mertz KR, Baddour LM, Bell JL, et al:
Breast cellulitis following breast conservation
therapy: A novel complication of medical
progress. Clin Infect Dis 26:481-486, 1998.
8. Loprinzi CL, Okuno SH, Pisansky TM,
et al: Postsurgical changes of the breast that
mimic inflammatory breast carcinoma. Mayo
Clin Proc 71:552-555, 1996.
9. Clarke D, Curtis JL, Martinez A, et al:
Fat necrosis of the breast simulating recurrent
carcinoma after primary radiotherapy in the
management of early-stage breast carcinoma.
Cancer 52:442-445, 1983.
10. Meric F, Buchholz TA, Mirza NQ, et al:
Long-term complications associated with
breast-conservation surgery and radiotherapy.
Ann Surg Oncol 9:543-549, 2002.
11. Boyages J, Bosch C, Langlands A, et al:
Breast conservation: Long-term Australian
data. Int J Radiat Oncol Biol Phys 24:253-
12. Wazer DE, Lowther D, Boyle T, et al:
Clinically evident fat necrosis in women treated
with high-dose-rate brachytherapy alone
for early-stage breast cancer. Int J Radiat Oncol
Biol Phys 50:107-111, 2001.
13. Perera F, Engel J, Holliday R, et al:
Local resection and brachytherapy confined to
the lumpectomy site for early breast cancer: A
pilot study. J Surg Oncol 65:263-267, 1997.
14. Bilgen IG, Ustun EE, Memis A: Fat
necrosis of the breast: Clinical, mammographic,
and songraphic features. Eur J Radiol 39:92-
15. Boyages J, Bilous M, Barraclough B, et
al: Fat necrosis of the breast following lumpectomy
and radiation therapy for early breast
cancer. Radiother Oncol 13:69-74, 1988.
16. Gerber L, Lampert M, Wood C, et al:
Comparison of pain, motion, and edema after
modified radical mastectomy vs local excision
with axillary dissection and radiation. Breast
Cancer Res Treat 21:139-145, 1992.
17. Fujishiro S, Mitsumori M, Kokubo M,
et al: Cosmetic results and complications after
breast conserving therapy for early breast cancer.
Breast Cancer 7:57-63, 2000.
18. Tengrup I, Tennvall-Nittby L, Christiansson
I, et al: Arm morbidity after breastconserving
therapy for breast cancer. Acta
Oncologica 39:393-397, 2000.
19. Lash TL, Silliman RA: Patient characteristics
and treatments associated with a decline
in upper-body function following breast
cancer therapy. J Clin Epidemiol 53:615-622,
20. Haid A, Kuehn T, Konstantiniuk P, et
al: Shoulder-arm morbidity following axillary
dissection and sentinel node only biopsy for
breast cancer. Eur J Surg Oncol 28:705-710,
21. Liljegren G, Holmberg L: Arm morbidity
after sector resection and axillary dissection
with or without postoperative radiotherapy
in breast cancer stage I. Results from a randomized
trial. Uppsala-Orebro Breast Cancer
Study Group. Eur J Cancer 33:193-199, 1997.
22. Mandelblatt JS, Edge SB, Meropol NJ,
et al: Sequelae of axillary lymph node dissection
in older women with stage 1 and 2 breast
carcinoma. Cancer 95:2445-2454, 2002.
23. Schrenk P, Rieger R, Shamiyeh A, et al:
Morbidity following sentinel lymph node bi-
References continued on following page.
opsy vs axillary lymph node dissection for
patients with breast carcinoma. Cancer 88:608-
24. Kwan W, Jackson J, Weir LM, et al:
Chronic arm morbidity after curative breast cancer
treatment: Prevalence and impact on quality
of life. J Clin Oncol 20:4242-4248, 2002.
25. Ernst MF, Voogd AC, Balder W, et al:
Early and late morbidity associated with axillary
levels I-III dissection in breast cancer. J
Surg Oncol 79:151-156 (incl discussion), 2002.
26. Tasmuth T, von Smitten K, Hietanen P,
et al: Pain and other symptoms after different
treatment modalities of breast cancer. Ann Oncol
27. Rayan G, Dawson L, Bezjak A, et al:
Prospective comparison of breast pain in patients
participating in a randomized trial of
breast-conserving surgery and tamoxifen with
or without radiotherapy. Int J Radiol Oncol
Biol Phys 55:154-161, 2003.
28. Bentzen SM, Overgaard M, Thames
HD: Fractionation sensitivity of a functional
endpoint: Impaired shoulder movement after
post-mastectomy radiotherapy. Int J Radiat
Oncol Biol Phys 17:531-537, 1989.
29. Ewing J: Radiation osteitis. Acta Radiol
30. Rubin P, Casarett G: Mature cartilage
and adult bone, in Clinical Radiation Pathology,
vol 2, p 557. Philadelphia, WB Saunders,
31. Howland WJ, Loeffler RK, Starchman
DE, et al: Postirradiation atrophic changes of
bone and related complications. Radiology
32. Rubin P: The radiographic expression
of radiotherapeutic injury: An overview. Semin
Roentgenol 9:5-13, 1974.
33. Langlands AO, Souter WA, Redpath
AT: Radiation osteitis following irradiation
for breast cancer. Clin Radiol 28:93-96, 1977.
34. Shimanovskaya K, Shiman A: Radiation
Injury of Bone. New York, Pergamon
35. DeSantos L, Libshitz H: Adult bone, in
Libshitz H (ed): Diagnostic Roentgenology of
Radiotherapy Change. Baltimore, Williams &
36. Clarke D, Martinez A, Cox RS: Analysis
of cosmetic results and complications in
patients with stage I and II breast cancer treated
by biopsy and irradiation. Int J Radiat Oncol
Biol Phys 9:1807-1813, 1983
37. Contant CM, van Geel AN, van der
Holt B, et al: The pedicled omentoplasty and
split skin graft (POSSG) for reconstruction of
large chest wall defects. A validity study of 34
patients. Eur J Surg Oncol 22:532-537, 1996.
38. Delanian S, Lefaix JL: Complete healing
of severe osteoradionecrosis with treatment
combining pentoxifylline, tocopherol,
and clodronate. Br J Radiol 75:467-469, 2002.
39. Feldmeier JJ, Heimbach RD, Davolt
DA, et al: Hyperbaric oxygen as an adjunctive
treatment for delayed radiation injury of the
chest wall: A retrospective review of twentythree
cases. Undersea Hyperb Med 22:383-
40. Hines GL, Lee G: Osteoradionecrosis
of the chest wall. Management of postresection
defects using Marlex mesh and a rotated
latissimus dorsi myocutaneous flap. Am
Surg 49:608-611, 1983.
41. Hultman CS, Culbertson JH, Jones
GE, et al: Thoracic reconstruction with the
omentum: Indications, complications, and
results. Ann Plast Surg 46:242-249, 2001.
42. Sato M, Tanaka F, Wada H: Treatment
of necrotic infection on the anterior
chest wall secondary to mastectomy and
postoperative radiotherapy by the application
of omentum and mesh skin grafting:
Report of a case. Surg Today 32:261-263,
43. Feldmeier JJ, Hampson NB: A systematic
review of the literature reporting
the application of hyperbaric oxygen prevention
and treatment of delayed radiation
injuries: An evidence-based approach. Undersea
Hyperb Med 29:4-30, 2002.
44. Carl UM, Feldmeier JJ, Schmitt G, et
al: Hyperbaric oxygen therapy for late sequelae
in women receiving radiation after
breast-conserving surgery. Int J Radiat Oncol
Biol Phys 49:1029-1031, 2001.
45. Gottlober P, Steinert M, Bahren W,
et al: Interferon-gamma in 5 patients with
cutaneous radiation syndrome after radiation
injury. Int J Radiat Oncol Biol Phys
46. Peter RU, Gottlober P, Nadeshina N,
et al: Gamma-gamma in survivors of the
Chernobyl power plant accident: New therapeutic
option for radiation-induced fibrosis.
Int J Radiat Oncol Biol Phys 45:147-152,
47. Futran ND, Trotti A, Gwede C: Pentoxifylline
in the treatment of radiation-related
soft tissue injury: Preliminary
observations. Laryngoscope 107:391-395,
48. Delanian S, Balla-Mekias S, Lefaix
JL: Striking regression of chronic radiotherapy
damage in a clinical trial of combined
pentoxifylline and tocopherol. J Clin Oncol
49. de la Rochefordiere A, Abner AL,
Silver B, et al: Are cosmetic results following
conservative surgery and radiation therapy
for early breast cancer dependent on
technique? Int J Radiat Oncol Biol Phys
50. Johansen J, Overgaard J, Rose C, et
al: Cosmetic outcome and breast morbidity
in breast-conserving treatment. Acta Oncologica
51. Taylor M, Perez C, Halverson K, et
al: Factors influencing cosmetic results after
conservation therapy for breast cancer.
Int J Radiat Oncol Biol Phys 31:753-764,
52. Vrieling C, Collette L, Fourquet A, et
al: The influence of patient, tumor and treatment
factors on the cosmetic results after
breast-conserving therapy in the EORTC
‘boost vs no boost' trial. Radiother Oncol
53. Beadle GF, Silver B, Botnick L, et al:
Cosmetic results following primary radiation
therapy for early breast cancer. Cancer
54. Harris JR, Levene MB, Svensson G, et
al: Analysis of cosmetic results following primary
radiation therapy for stages I and II carcinoma
of the breast. Int J Radiat Oncol Biol
Phys 5:257-261, 1979.
55. Moody AM, Mayles WP, Bliss JM, et
al: The influence of breast size on late radiation
effects and association with radiotherapy
dose inhomogeneity. Radiother Oncol 33:106-
56. Wazer DE, DiPetrillo T, Schmidt-Ullrich
R, et al: Factors influencing cosmetic outcome
and complication risk after conservative
surgery and radiotherapy for early-stage breast
carcinoma. J Clin Oncol 10:356-363, 1992.
57. Johansson S, Svensson H, Denekamp J:
Dose response and latency for radiation-induced
fibrosis, edema, and neuropathy in breast
cancer patients. Int J Radiat Oncol Biol Phys
58. Fisher B, Anderson S, Bryant J, et al:
Twenty-year follow-up of a randomized trial
comparing total mastectomy, lumpectomy, and
lumpectomy plus irradiation for the treatment
of invasive breast cancer. N Engl J Med
59. Fisher B, Bryant J, Dignam J, et al:
Tamoxifen, radiation therapy, or both for prevention
of ipsilateral breast tumor recurrence
after lumpectomy in women with invasive
breast cancers of one centimeter or less. J Clin
Oncol 20:4141-4149, 2002.
60. Veronesi U, Marubini F, Mariani L, et
al: Radiotherapy after breast-conserving surgery
in small breast carcinoma: Long-term
results of a randomized trial. Ann Oncol
61. Huang E, Buchholz TA, Meric F, et al:
Classifying local disease recurrences after
breast conservation therapy based on location
and histology. Cancer 95:2059-2067, 2002.
62. Fredriksson I, Liljegren G, Arnesson
LG, et al: Local recurrence in the breast after
conservative surgery-a study of prognosis
and prognostic factors in 391 women. Eur J
Cancer 38:1860-1870, 2002.
63. Doyle T, Schultz DJ, Peters C, et al:
Long-term results of local recurrence after
breast conservation treatment for invasive
breast cancer. Int J Radiat Oncol Biol Phys
64. Kurtz JM, Jacquemier J, Amalric R, et
al: Is breast conservation after local recurrence
feasible? Eur J Cancer 27:240-244,
65. Deutsch M: Repeat high-dose externalbeam
irradiation for in-breast tumor recurrence
after previous lumpectomy and whole breast
irradiation. Int J Radiat Oncol Biol Phys
66. Resch A, Fellner C, Mock U, et al:
Locally recurrent breast cancer: Pulse dose
rate brachytherapy for repeat irradiation following
lumpectomy-a second chance to preserve
the breast. Radiology 225:713-718, 2002.